A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

NCT07406282 · clinicaltrials.gov ↗

RECRUITING

Status

1400

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms
Metastatic Hormone-Sensitive Prostate Cancer

Interventions

DRUG: Darolutamide
DRUG: Abiraterone acetate
DRUG: Enzalutamide
DRUG: Apalutamide

Sponsor

Bayer